In one of the biggest M&A deals involving artificial intelligence-focused drug developers to date, Recursion Pharma has agreed to join with Exscientia in an all-stock transaction valued at $688 ...
Marta Gouger (our Times News editor) gave me a shot at writing this column, I had no idea it would be continuing this long.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback